Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-γ and cisplatin

International Journal of Cancer

Volumn 80, Issue 4, 1999, Pages 564-572

  Moers, Cordula ^a   Warskulat, Ulrich ^a   Müschen, Markus ^a,b   Even, Jos ^b   Niederacher, Dieter ^a   Josien, Régis ^c   Koldovsky, Ursula ^a   Beckmann, Matthias W ^a   Häussinger, Dieter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b INSTITUT PASTEUR   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; FAS ANTIGEN;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LIGAND BINDING; MEMBRANE BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STROMA CELL; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE; VULVA CARCINOMA;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CISPLATIN; FAS LIGAND PROTEIN; FEMALE; HUMANS; INTERFERON TYPE II; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED; VULVAR NEOPLASMS;

EID: 0033521875     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990209)80:4<564::AID-IJC14>3.0.CO;2-X     Document Type: Article

References (21)

1. BUECHNER, S., WERNLI, M., HARR, T., HAHN, S., ITIN, P. and ERB, P., Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-l/ Fas)-CD95 ligand-induced suicide. J. clin. Invest., 100, 2691-2696 (1997).
2. CRUM, C.P., MCLACHLIN, C.M., TATE, J.E. and MUTTER, G.L., Pathobiology of vulvar squamous neoplasia. Curr. Opin. Obstetr. Gynecol., 9, 63-69 (1997).
3. ESAKI, T., NAKANO, S., MASUMOTO, N., FUJISHIMA, H. and NIHO, Y., Schedule-dependent reversion of acquired cisplutin resistance by 5-fluorouracil in a newly established cisplatin-resistanT HST-1 human squamous carcinoma cell line. Int. J. Cancer, 65, 479-484 (1996).
4. FRIESEN, C., HERR, I., KRAMMER, P.H. and DEBATIN, K.M., Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature (Med.). 2, 574-577 (1996).
5. GUTIERREZ-STEIL, C., WRONE-SMITH, T., SUN, X., KRUEGER, J.G., COVEN, T. and NICKOLOFF, B.J., Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L). J. clin. Invest., 101, 33-39 (1998)
6. HAHNE, M., RIMOlDI, D., SCHRÖTER, M., ROMERO, P., SCHREIER, M., FRENCH, L.E., SCHNEIDER, P., BORNAND, T., FONTANA, A., LIENARD, D., CEROTTINI, J.C. and TSCHOPP, J., Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science, 274, 1363-1366 (1996).
7. HUG, H., Fas-mediated apoptosis in tumor formation and defense. Biol. Chem., 378, 1405-1412 (1997).
8. HUGHES, D.P.M. and CRISPE, N.I., A naturally occurring soluble isoform of murine Fas generated by alternative splicing. J. exp. Med., 182, 1395-1401 (1995).
9. IWAYA, T., MAESAWA, C., TAMURA, G., SATO, N., IKEDA, K., SASAKI, A., OTHUKA, K., ISHIDA, K., SAITO, K. and SATODATE, R., Esophageal carcinosarcoma: a genetic analysis. Gastroenterology, 113, 973-977 (1997).
10. LANDOWSKI, T.H., GLEASON-GUZMAN, M.C. and DALTON, W.S., Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood, 89, 1854-1861 (1997).
11. LEITHÄUSER, F., DHEIN, J., MECHTERSHEIMER, G., KORETZ, K., BRÜDERLEIN, S., HENNE, C., SCHMIDT, A., DEBATIN, K.M., KRAMMER, P.H. and MÖLLER, P., Constitutive and induced expression of APO-1, a new member of the nerve growth factor/ tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest., 69, 415-429 (1993).
12. MUKAKI, Y., YOSHIOKA, C., FUKUDA, J., HANEJI, T. and KOBAYASHI, N., Immunohistochemical detection of fas antigen in oral epithelia. J. Oral. Pathol. Med., 26, 57-62 (1997).
13. MÜSCHEN, M., WARSKULAT, U., DOUILLARD, P., GILBERT, E. and HÄUSSINGER, D., Regulation of CD95 (Apo-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells. Hepatology. 27, 200-208 (1998).
14. MÜSCHEN, M., WARSKULAT, U., HÄUSSINGER, D., MOERS, C., SIMON, D. and EVEN, J., Deranged CD95-system in a case of Churg-Strauss vasculitis. Gastroenterology. 114, 1351-1352 (1998).
15. NAKAJIMA, M., NAKAJIMA, A., KAYAGAKI, N., HONDA, M., YAGITA, H. and OKUMURA, K., Expression of Fas ligand and its receptor in cutaneous lupus: implication in tissue injury, Clin. Immunol. Immunopathol., 83, 223-229 (1997).
16. PANNETIER, C., DELASSUS, S., DARCHE, S., SAUCIER, C. and KOURILSKY, P., Quantitative titration of nucleic acids by enzymatic amplification reactions run to saturation. Nucl. Acids Res. 21, 577-583 (1993).
17. TOBIAS, D.H., SMITH, H.O., JONES, J.G., ANDERSON, P., RUNOWICZ, C.D. and GOLDBERG, G.L., Cutaneous metastases from squamous cell carcinoma of the vulva. Europ. J. Gynecol. Oncol., 16, 382-386 (1995).
18. TOMITA, Y., KAWASAKI, T., BILIM, V., TAKEDA, M. and TAKAHASHI, K., Tetrapeptide DEVD-aldehyde or YVAD-chlormethylketone inhibits Fas/ Apo-1 (CD95)-mediated apoptosis in renal-cell-cancer cells. Int. J. Cancer, 68, 132-135 (1996).
19. TRAUTH, B.C., KLAS, C., PETERS, A.M.J., MATZKU, S., MÖLLER, P., FALK, W., DEBATIN, K.M. and KRAMMER, P.H., Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245, 301-305 (1989).
20. WELTERS, M.J., FICHTINGER-SCHEPMAN, A.M., BAAN, R.A., HERMSEN, M.A., VAN DER VUGH, W.J., CLOOS, J. and BRAAKHUIS, B.J., Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines. Int. J. Cancer, 71, 410-415 (1997).
21. WRONE-SMITH, T., JOHNSON, T., NELSON, B., BOISE, L.H., THOMPSON, C.B., NUNEZ, G. and NICKOLOFF, B.J., Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Amer. J. Patholo., 146, 1079-1088 (1995).